ReviewApplied biochemistry and biotechnology2026
Neural Stem Cells in Multiple Sclerosis: A Comprehensive Review of Preclinical and Clinical Evidence for CNS Repair and Translational Hurdles.
Review in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Multiple sclerosis (MS) is a chronic, immune-mediated, neurodegenerative disease of the central nervous system (CNS) characterized by inflammation, demyelination, and axonal destruction. MS impacts about 2.6 million individuals worldwide, typically presenting a wide array of clinical manifestations, such as motor, sensory, visual, and dementia, often leading to progressive disability. This progressive condition and the accumulation of handicaps draw attention to a crucial unmet need for therapies able to preserve neurons, encourage myelin regeneration, and restore neurological function. Although present conventional treatments mostly target the inflammatory aspects of MS, their effectiveness in treating the underlying neurodegeneration and supporting central nervous system repair is still limited. Recently, stem cell-based therapy and regenerative medicine have become some of the most promising approaches for treating MS. However, progress is subject to challenges and achievements are limited. The current study thoroughly investigates the findings of preclinical and clinical studies on neural stem cell (NSC)-based therapies for MS and highlights the related challenges. Study investigates its possible modes of action, treatment effectiveness, major earlier challenges, and emerging questions in transferring NSC-based therapies into clinical practice, aiming to improve neuroprotection, promote remyelination, and facilitate the repair of damaged CNS tissue. NSC-based therapies hold great potential as a regenerative therapy for MS, however, fundamental questions remain about the optimal delivery, long-term survival, functional integration, and potential immunological responses. To sum up, NSC-based therapies represent a promising new frontier in the next generation of treatments for MS. However, further comprehensive studies are required to conclusively confirm their safety, effectiveness, and long-term advantages.
Indexed as
Identifiers
42547698What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.